Moderna, Inc. (MRNA)
Strength Seen in Moderna (MRNA): Can Its 13.9% Jump Turn into More Strength?
Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
S&P 500 Gains and Losses Today: Meta Stock Drops After Earnings; Moderna Surges
Shares of a social media juggernaut slumped as investors balked at its rapidly accelerating spending on artificial intelligence, while reports of potential partnership or buyout talks helped a vaccine maker's shares shoot higher.
Earnings Preview: Moderna (MRNA) Q3 Earnings Expected to Decline
Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Moderna (MRNA) Outperforms Broader Market: What You Need to Know
Moderna (MRNA) reached $26.74 at the closing of the latest trading day, reflecting a +1.87% change compared to its last close.
Moderna Vs BioNTech: Who's Winning The Post-COVID Race
Moderna and BioNTech were the main 'saviors' of people and economies from COVID-19. However, since the pandemic ended, their stock prices have fallen by more than 70%. Recognizing this, BioNTech and Moderna continue to actively diversify their portfolios of experimental drugs and vaccines toward cancer treatment.
Moderna (MRNA) Registers a Bigger Fall Than the Market: Important Facts to Note
In the closing of the recent trading day, Moderna (MRNA) stood at $26.25, denoting a -1.83% move from the preceding trading day.
Moderna: Q3 Earnings Preview - I Fear A Halloween Horror Show (Downgrade)
Moderna, Inc. faces significant uncertainty ahead of Q3 earnings, with heavy reliance on COVID vaccine revenues and limited pipeline progress. Moderna's cost-cutting measures and cash reserves provide a buffer, but lack of new product launches and market competition challenge near-term growth. Oncology pipeline, especially mRNA-4157 and mRNA-4359, offers long-term promise, but regulatory and reimbursement hurdles remain substantial.
Moderna (MRNA) Surpasses Market Returns: Some Facts Worth Knowing
In the closing of the recent trading day, Moderna (MRNA) stood at $27.92, denoting a +2.12% move from the preceding trading day.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Moderna (MRNA) Beats Stock Market Upswing: What Investors Need to Know
Moderna (MRNA) concluded the recent trading session at $28.38, signifying a +2.83% move from its prior day's close.
Moderna (MRNA) Recently Broke Out Above the 50-Day Moving Average
From a technical perspective, Moderna (MRNA) is looking like an interesting pick, as it just reached a key level of support. MRNA recently overtook the 50-day moving average, and this suggests a short-term bullish trend.
MRNA Stock Rises as Updated COVID-19 Jab Shows Strong Immune Response
Moderna jumps after its updated formulation of Spikevax shows an over 8-fold increase in neutralizing antibodies against the LP.8.1 COVID-19 variant in phase IV study.
